Katherine Laiton-Donato

Mrs. Katherine Laiton-Donato


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
KLKatherine Laiton-Donato
Katherine Laiton-Donato
CFCarlos Franco-Muñoz
Carlos Franco-Muñoz
DÁDiego A. Álvarez-Díaz
Diego A. Álvarez-Díaz
HRHector Alejandro Ruiz-Moreno
Hector Alejandro Ruiz-Moreno
JUJosé A. Usme-Ciro
José A. Usme-Ciro
MMMarcela Mercado-Reyes
Marcela Mercado-Reyes

1 October 2020 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
DÁDiego Alejandro Álvarez-Díaz
Diego Alejandro Álvarez-Díaz
CFCarlos Franco-Muñoz
Carlos Franco-Muñoz
KLKatherine Laiton-Donato
Katherine Laiton-Donato
JUJose A Usme-Ciro
Jose A Usme-Ciro
NFNicolás D. Franco-Sierra
Nicolás D. Franco-Sierra
MMMarcela Mercado-Reyes
Marcela Mercado-Reyes

1 December 2020 in Emerging Infectious Diseases
Verified
Journal Article
Closed access
KLKatherine Laiton-Donato
Katherine Laiton-Donato
CVChristian Julián Villabona-Arenas
Christian Julián Villabona-Arenas
JUJosé A. Usme-Ciro
José A. Usme-Ciro
CFCarlos Franco-Muñoz
Carlos Franco-Muñoz
DÁDiego A. Álvarez-Díaz
Diego A. Álvarez-Díaz
MMMarcela Mercado-Reyes
Marcela Mercado-Reyes
Coronavirus disease (COVID-19) in Colombia was first diagnosed in a traveler arriving from Italy on February 26, 2020. However, limited data are available on the origins and number of introductions of COVID-19 into the country. We sequenced the causative agent of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), from 43 clinical samples we collected, along with another 79 genome sequences available from Colombia. We investigated the emergence and importation routes for SARS-CoV-2 into Colombia by using epidemiologic, historical air travel, and phylogenetic observations. Our study provides evidence of multiple introductions, mostly from Europe, and documents >12 lineages. Phylogenetic findings validate the lineage diversity, support multiple importation events, and demonstrate the evolutionary relationship of epidemiologically linked transmission chains. Our results reconstruct the early evolutionary history of SARS-CoV-2 in Colombia and highlight the advantages of genome sequencing to complement COVID-19 outbreak investigations.

24 January 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
DÁDiego Alejandro Álvarez-Díaz
Diego Alejandro Álvarez-Díaz
AMAna Muñoz
Ana Muñoz
PTPilar Tavera-Rodríguez
Pilar Tavera-Rodríguez
MHMaría T. Herrera-Sepúlveda
María T. Herrera-Sepúlveda
HRHector Alejandro Ruiz-Moreno
Hector Alejandro Ruiz-Moreno
MMMarcela Mercado-Reyes
Marcela Mercado-Reyes
Global surveillance programs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are showing the emergence of variants with mutations in the spike protein. Genomic and laboratory surveillance are important to determine if these variants may be more infectious or less susceptible to antiviral treatments and vaccine-induced antibodies. Three of the most predominant SARS-CoV-2 variants in Colombia during the epidemiological peaks of 2021 were isolated: Mu, a variant of interest; Gamma, a variant of concern; B.1.111, which lacks genetic markers associated with greater virulence. Microneutralization assays were performed by incubating 120 mean tissue culture infectious doses (TCID50) of each SARS-CoV-2 isolate with five two-fold serial dilutions of sera from 31 BNT162b2-vaccinated volunteers. The mean neutralization titer (MN50) was calculated by the Reed–Muench method. At the end of August, Mu represented 49% of coronavirus disease 2019 (COVID-19) cases in Colombia, followed by 25% of Gamma. In contrast, B.1.111 became almost undetectable. The evaluation of neutralizing antibodies suggests that patients vaccinated with BNT162b2 generate neutralizing antibody titers against the Mu variant at significantly lower concentrations relative to B.1.111 and Gamma. This study shows the importance of continuing surveillance programs of emerging variants, as well as the need to evaluate the neutralizing antibody response induced by other vaccines.

8 May 2019 in Virology Journal
Verified
Journal Article
Open access
PDF file
KLKatherine Laiton-Donato
Katherine Laiton-Donato
DÁDiego Alejandro Álvarez-Díaz
Diego Alejandro Álvarez-Díaz
DPDioselina Peláez-Carvajal
Dioselina Peláez-Carvajal
MMMarcela Mercado-Reyes
Marcela Mercado-Reyes
NANadim Ajami
Nadim Ajami
JUJose A Usme-Ciro
Jose A Usme-Ciro
Dengue is hyperendemic in Colombia, where a cyclic behavior of serotype replacement leading to periodic epidemics has been observed for decades. This level of endemicity favors accumulation of dengue virus genetic diversity and could be linked to disease outcome. To assess the genetic diversity of dengue virus type 2 in Colombia, we sequenced the envelope gene of 24 virus isolates from acute cases of dengue or severe dengue fever during the period 2013–2016. The phylogenetic analysis revealed the circulation of the Asian-American genotype of dengue virus type 2 in Colombia during that period, the intra-genotype variability leading to divergence in two recently circulating lineages with differential geographic distribution, as well as the presence of nonsynonymous substitutions accompanying their emergence and diversification.

30 October 2020 in Biomédica
Verified
Journal Article
Open access
PDF file
FDFrancisco Diaz
Francisco Diaz
WAWbeimar Aguilar-Jiménez
Wbeimar Aguilar-Jiménez
LFLizdany Flórez
Lizdany Flórez
GVGladys Valencia
Gladys Valencia
KLKatherine Laiton-Donato
Katherine Laiton-Donato
MRMaría Teresa Rugeles
María Teresa Rugeles
Introducción. El nuevo coronavirus causante de un brote de enfermedad respiratoria aguda en China en diciembre de 2019 se identificó como SARS-CoV-2. La enfermedad, denominada COVID-19, fue declarada pandemia por la Organización Mundial de la Salud (OMS). El primer caso de COVID-19 en Colombia se reportó el 6 de marzo de 2020; en este estudio se caracterizó un aislamiento temprano del virus SARS-CoV-2 de una muestra ecolectada en abril de 2020.Objetivos. Describir y caracterizar una cepa temprana a partir de un aislamiento de SARSCoV-2 durante la pandemia en Colombia.Materiales y métodos. Se obtuvo una muestra de un paciente con COVID-19 confirmada por qRT-PCR; la muestra fue inoculada en diferentes líneas celulares hasta la aparición del efecto citopático. Para confirmar la presencia de SARS-CoV-2 en el cultivo, se utilizó la qRT-PCR a partir de los sobrenadantes, la inmunofluorescencia indirecta (IFI) en células Vero-E6, así como microscopía electrónica y secuenciación de nueva generación (nextgeneration sequencing).Resultados. Se confirmó el aislamiento de SARS-CoV-2 en células Vero-E6 por la aparición del efecto citopático tres días después de la infección, así como mediante la qRT-PCR y la IFI positiva con suero de paciente convaleciente positivo para SARS-CoV-2. Además, en las imágenes de microscopía electrónica de trasmisión y de barrido de células infectadas se observaron estructuras compatibles con viriones de SARS-CoV-2. Por último, se obtuvo la secuencia completa del genoma, lo que permitió clasificar el aislamiento como linaje B.1.5.Conclusiones. La evidencia presentada en este artículo permite confirmar el primer aislamiento de SARS-CoV-2 en Colombia. Además, muestra que esta cepa se comporta en cultivo celular de manera similar a lo reportado en la literatura para otros aislamientos y que su composición genética está acorde con la variante predominante en el mundo. Finalmente, se resalta la importancia que tiene el aislamiento viral para la detección de anticuerpos, para la caracterización genotípica y fenotípica de la cepa y para probar compuestos con potencial antiviral.